Express Scripts (ESRX) Upgraded to “Market Perform” by Sanford C. Bernstein

Express Scripts (NASDAQ:ESRX) was upgraded by research analysts at Sanford C. Bernstein from an “underperform” rating to a “market perform” rating in a research report issued on Wednesday.

Other research analysts also recently issued reports about the company. TheStreet upgraded Express Scripts from a “c+” rating to a “b-” rating in a report on Monday. Mizuho set a $67.00 price target on Express Scripts and gave the company a “hold” rating in a report on Tuesday, October 24th. Robert W. Baird reiterated a “hold” rating and issued a $56.00 price target on shares of Express Scripts in a report on Friday, September 1st. Morgan Stanley lifted their price target on Express Scripts from $52.00 to $57.00 and gave the company an “underweight” rating in a report on Thursday, August 10th. Finally, ValuEngine upgraded Express Scripts from a “hold” rating to a “buy” rating in a report on Monday. Six research analysts have rated the stock with a sell rating, eleven have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $70.67.

Shares of Express Scripts (NASDAQ ESRX) opened at $67.84 on Wednesday. The company has a current ratio of 0.73, a quick ratio of 0.61 and a debt-to-equity ratio of 0.86. The firm has a market capitalization of $38,603.98, a price-to-earnings ratio of 9.96, a price-to-earnings-growth ratio of 1.01 and a beta of 0.88. Express Scripts has a 1 year low of $55.80 and a 1 year high of $77.25.

Express Scripts (NASDAQ:ESRX) last issued its earnings results on Tuesday, October 24th. The company reported $1.90 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $1.90. The business had revenue of $24.68 billion during the quarter, compared to analyst estimates of $25.68 billion. Express Scripts had a return on equity of 25.46% and a net margin of 3.64%. Express Scripts’s revenue was down 2.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.74 EPS. equities research analysts predict that Express Scripts will post 7.01 earnings per share for the current year.

In related news, Director Woodrow A. Myers, Jr. sold 3,900 shares of the business’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $63.93, for a total transaction of $249,327.00. Following the transaction, the director now directly owns 11,500 shares in the company, valued at approximately $735,195. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Timothy C. Wentworth bought 8,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 31st. The shares were acquired at an average price of $61.13 per share, for a total transaction of $489,040.00. Following the completion of the purchase, the chief executive officer now owns 98,628 shares in the company, valued at $6,029,129.64. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 5,121 shares of company stock worth $325,920. 0.68% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of ESRX. Endurant Capital Management LP grew its stake in Express Scripts by 22.8% during the 1st quarter. Endurant Capital Management LP now owns 118,027 shares of the company’s stock valued at $7,779,000 after purchasing an additional 21,900 shares during the last quarter. Westwood Holdings Group Inc. grew its stake in Express Scripts by 15.6% during the 1st quarter. Westwood Holdings Group Inc. now owns 69,700 shares of the company’s stock valued at $4,594,000 after purchasing an additional 9,400 shares during the last quarter. Cambria Investment Management L.P. grew its stake in Express Scripts by 1.2% during the 1st quarter. Cambria Investment Management L.P. now owns 17,176 shares of the company’s stock valued at $1,132,000 after purchasing an additional 209 shares during the last quarter. Tudor Investment Corp ET AL grew its stake in Express Scripts by 274.3% during the 1st quarter. Tudor Investment Corp ET AL now owns 234,995 shares of the company’s stock valued at $15,489,000 after purchasing an additional 172,209 shares during the last quarter. Finally, Caxton Associates LP purchased a new stake in Express Scripts during the 1st quarter valued at about $468,000. Institutional investors and hedge funds own 88.44% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Express Scripts (ESRX) Upgraded to “Market Perform” by Sanford C. Bernstein” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.com-unik.info/2017/12/06/express-scripts-esrx-upgraded-to-market-perform-by-sanford-c-bernstein.html.

About Express Scripts

Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).

Analyst Recommendations for Express Scripts (NASDAQ:ESRX)

What are top analysts saying about Express Scripts Holding Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Express Scripts Holding Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit